Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A treatment offer develops through customer stories, product education, the care process and a clear purchase entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The post format blends into a feed, so the ad reads like something a friend shared before it reads like an offer. The red underline under the per-day price pulls the eye to the number first, and a daily figure makes a recurring program feel small. The list underneath is easy to scan because every line starts the same way, with UNLIMITED in caps, and the badges plus the button sit together at the bottom where the decision happens.
The per-day price doesn't appear anywhere the viewer goes next. The fine print restates it as $166 a month with a $499 renewal every 11 weeks, and the landing page only shows monthly and three-month prices, so the number that earned the click has to be translated after it. The reaction count on the mocked-up post is part of the design rather than a real post's engagement, and a real member post would carry more weight. Run the per-day figure on the page next to the $499 plan, and test a version built from a real community post with permission.
The familiar post layout makes the ad feel native to the feed.
A daily price makes a recurring cost feel small and gets read first.
The repeated UNLIMITED makes the inclusions scannable and stacks value under the price.
Outside proof sits next to the action so the decision feels safer.
Tirzepatide at about $5.94 a day (if approved), which the fine print translates to $166 a month on a three-month minimum that automatically renews for $499 every 11 weeks.
The ad sends people to tirzepatidewoo.brellohealth.com, a dedicated Tirzepatide offer page rather than the homepage or a quiz, and it's one of 18 Brello ads in the library that point there. The page picks up the value list, because its plan and purchase entry under What makes Brello different covers the classes, community and provider access the post promises. It doesn't pick up the headline number. The hero sells $166 a month and a $499 plan with $749 crossed out, so the $5.94 a day framing disappears at the click. Adding the daily figure under the hero price would let the ad's main promise land on the page intact.
Brello's dedicated Tirzepatide offer page opens on a $166 a month special with the three-month plan box, then moves through reviews, treatment education, a four-step care path, inclusions and FAQs. It's where 18 Brello ads in the library land, all static image ads, built on emotional moments, native-style text posts and offer or inclusion lists.
A price lock banner, the vial with a $166 badge, and a plan box with the $499 three-month plan, Trustpilot rating, transfer note and intake explanation, answering what it costs and what happens when you pay.
Trusted by 80,000+ members with a Trustpilot rating and review cards about community, customer service and members' own results, answering whether people like you have done this.
A deeper look inside Tirzepatide, with a short explanation, a list of what studies examine, footnoted sources and a results-may-vary note, answering what the medication is.
A straightforward path to care in four photo steps (select your plan, provider review, ships to your door, ongoing support), answering how the process works.
What makes Brello different, with six inclusions beside a photo and a Take the First Step button, answering what you get beyond the medication.
Six questions on approval, refunds, timelines and replacements, then the study references, disclaimers and plan terms, answering the last practical doubts.
Read the full breakdown of this page
One of 22 Brello Health ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.